News & Updates
Filter by Specialty:

MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
19 Jan 2023
Pain, discomfort persist in JIA patients despite medication use
Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.
Pain, discomfort persist in JIA patients despite medication use
18 Jan 2023
Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.
Can RA patients taper MTX from targeted therapy?
18 Jan 2023
Fluvoxamine strikes out in mild-to-moderate COVID-19
Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.
Fluvoxamine strikes out in mild-to-moderate COVID-19
18 Jan 2023
START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC
START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.